Peeter Padrik, MD, PhD | Antegenes
Competition Sponsor: EIT Health of the European Union
Awardee Year: 2023
Antegenes is an Estonian health technology company developing and implementing genetic tests for clinical use based on polygenic risk score technology. These tests effectively identify individual genetic risk components for breast, prostate, colorectal cancers, and skin melanoma and include clinical recommendations for personalised cancer prevention. As CE-marked in vitro medical devices, the tests comply with EU regulatory standards. Based on the tests and integrated services, we enable the implementation of accurate, personalized cancer screening programs. Our comprehensive approach has the potential to contribute to a 30-40% reduction in mortality rates for these prevalent diseases, transforming the landscape of cancer prevention and care.